文献速递关节外科创伤骨科骨质疏松与代谢性骨病

全髋关节置换术前使用双膦酸盐:无论治疗时长均安全

Preoperative bisphosphonates in total hip arthroplasty : safe regardless of treatment duration.
PubMed 文献 · Bone Joint J · 2025-12-01

基于韩国全国医保数据库的队列研究显示,全髋关节置换术前使用双膦酸盐≥6个月不增加假体周围骨折和翻修风险,术后使用双膦酸盐与翻修风险降低相关(HR 0.74)。术前使用超过三年者假体周围骨折风险更低(HR 0.39)。

要点

  • 术前双膦酸盐暴露不是假体周围骨折或翻修的风险因素。
  • 术后双膦酸盐降低翻修风险(HR 0.74,95%CI 0.59-0.92;p=0.008)。
  • 术前使用超过三年者假体周围骨折风险更低(HR 0.39,95%CI 0.14-0.96;p=0.041)。

核心结论

  • 全髋关节置换术前使用双膦酸盐≥6个月不增加假体周围骨折和翻修风险,甚至可能降低此类风险,支持无论治疗时长均安全。
  • 合并症和髋部骨折等患者相关因素,而非双膦酸盐使用本身,是全髋关节置换术后假体周围并发症的关键风险因素。

研究设计与样本

  • 使用韩国全国医保索赔数据库,纳入年龄≥50岁接受单侧全髋关节置换术并围手术期使用双膦酸盐的患者。
  • 患者分为术前术后均用组(Pre & Post)、仅术后用组(Post Only)和对照组(术前术后均未用双膦酸盐)。
  • 倾向性评分匹配:术前术后均用组与仅术后用组按1:1匹配,各治疗组与相应对照组按1:5匹配。
  • 术前术后均用组按术前累计双膦酸盐使用时长分为三个亚组:6个月至1年、1至3年、超过3年。

主要发现

  • 倾向性评分匹配平衡基线特征后,与对照组相比,术前双膦酸盐暴露不是假体周围骨折或翻修的风险因素。
  • 与对照组相比,术后双膦酸盐降低全髋关节置换术后翻修风险(HR 0.74,95%CI 0.59-0.92;p=0.008)。
  • 髋部骨折是假体周围骨折和翻修的风险因素,年龄较大和Charlson合并症指数较高增加假体周围骨折风险,糖尿病增加翻修风险。
  • 亚组分析显示,术前术后均用组中超过3年亚组的假体周围骨折风险显著更低(HR 0.39,95%CI 0.14-0.96;p=0.041)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Recent studies have suggested that preoperative bisphosphonate (BP) use increases complications after total hip arthroplasty (THA), compared with THA in BP-naive patients. This study aimed to determine whether preoperative BP is associated with adverse surgical outcomes in patients receiving perioperative BP therapy, and whether duration of preoperative BP affected complication risk. METHODS: Using a nationwide Korean claims database, patients aged ≥ 50 years undergoing unilateral THA with perioperative BP were analyzed. Patients were categorized into 'Pre & Post' (BP use before and after surgery), 'Post Only' (BP use only after surgery), or control groups (no BP use before and after THA). Propensity score-matching (PSM) was performed: 1:1 ratio between the Pre & Post and Post Only groups and 1:5 between each treatment group and their respective controls. The Pre & Post group was further stratified into three subgroups based on cumulative BP duration before THA (six months to one year; one to three years; and more than three years). Outcomes including periprosthetic fracture (PPF) and revision were analyzed. RESULTS: After PSM balanced baseline characteristics, preoperative BP exposure was not a risk factor for PPF or revision compared with controls. Postoperative BP reduced revision risk after THA compared with the control group (hazard ratio (HR) 0.74 (95% CI 0.59 to 0.92); p = 0.008). Hip fracture was a risk factor for both PPF and revision, whereas older age and higher Charlson Comorbidity Index increased PPF risk, and diabetes increased revision risk. Sub-group analysis showed that the 'more than three-year' group showed a significantly lower risk of PPF (HR 0.39 (95% CI 0.14 to 0.96); p = 0.041) in the Pre & Post group. CONCLUSION: Preoperative use of BP ≥ six months before THA does not increase the risk of PPF and revision, and may even lower such risk, supporting safety regardless of treatment duration. Patient-related factors, such as comorbidities and hip fracture, rather than BP use itself, was a key risk factor for periprosthetic complications after THA.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Hong SH, Yu YJ, Han SB, et al. Preoperative bisphosphonates in total hip arthroplasty : safe regardless of treatment duration. Bone Joint J. 2025. PMID: 41319705. doi:10.1302/0301-620X.107B12.BJJ-2025-0280.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。